Jonathan Schechter is Director at PharmaCyte Biotech, Inc. (PMCB). SEC records also connect Schechter to Oblong, Inc. (OBLG) and TAO Synergies Inc. (TAOX). Schechter has reported 11 insider filings with the SEC since 2025. The most recent filing was in July 2026.
Every role Jonathan Schechter has reported on a Form 4, reconstructed from the filings themselves. Reporting insiders must state their relationship to the issuer (officer title, director seat, or 10% ownership) on every filing.
PharmaCyte Biotech, Inc. (PMCB)1 filingUpdated Aug 31, 2026
Jonathan Schechter is Director of PharmaCyte Biotech, Inc. (PMCB). 9 SEC Form 4 filings on record going back to 2025, most recently on 17 July 2026. Most recent open-market trade: bought $17K of PMCB on 7 January 2026. Lifetime open-market purchases: $108K. Historical track record: 2/5 stars across 6 tracked purchases.
Every recent SEC Form 4 transaction Jonathan Schechter has reported, most recent first.
InsiderAlpha computes a forward-return-based score for every insider with enough Form 4 purchase history. The metrics below reflect realized performance after each tracked open-market purchase.
| Metric | Value |
|---|---|
| InsiderAlpha rating | ★★☆☆☆ (2/5) |
| Total purchases tracked | 6 |
| Purchases with forward-return data | 5 |
| 30-day win rate | 40% |
| 90-day win rate | 0% |
| Avg 5-day return | +11.67% |
| Avg 30-day return | -2.14% |
| Avg 90-day return | -11.18% |
| Best 30-day return |
InsiderAlpha's records for Jonathan Schechter go back to 2025: 9 primary Form 4 filings, an average of 4.5 per year. The typical open-market purchase is $18K (6 buys totaling $108K). The largest single buy on record is $27K of OBLG in 2025. No transaction on record carries a Rule 10b5-1 flag - the filings look discretionary rather than pre-scheduled, which makes their timing more informative as a signal.
Insiders who reported open-market trades in the last 12 months at the companies Jonathan Schechter files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
Other corporate insiders with significant SEC Form 4 track records on InsiderAlpha:
Jonathan Schechter is a corporate insider, tracked as Director of PharmaCyte Biotech, Inc. (PMCB). InsiderAlpha holds 9 primary Form 4 filings for them, the earliest from 2025, updated as new SEC EDGAR filings are processed.
1 primary Form 4 filing in the last 90 days, covering 1 company.
Recorded transactions: 6 open-market purchases ($108K) and 0 open-market sales across all tracked filings.
Across 6 tracked purchases, Jonathan Schechter averaged -2.1% avg 30-day return with a 40% 30-day win rate. InsiderAlpha rates the track record at 2/5 stars.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
A free account opens the full scored daily plan and every past day, a watchlist for any ticker, and 3 months of price history on every company page. No card.
Free plan available · Paid plans start with a 7-day free trial
$PMCB PharmaCyte Biotech, Inc.20.0K shares @ $0.78$16K
| +11.30% |